KalshiVerfügbarkeit prüfenKYC erforderlich2% GebührVerifizierte AuflösungsdatenGrob kalibriertAktuelle implizite WahrscheinlichkeitJa 98%
Marktqualitat
44 / 100
Niedrige Qualität24h-Volumen
0 €
Liquidität
922,9 €
Niedrige LiquiditätGeld / Brief
80.0% / 86.0%
Spread
6.0 pt
Breiter SpreadMarktdaten
Aktualisiert vor 22 Minuten
17. Juni 26, 21:001. Jan. 27, 4:59
Trends
Nur virtuelles Guthaben – kein echtes GeldKeine Finanzberatung
Gewähltes Ergebnis
Yes98%
Volumentrend
$8123. Juli10T Daten26. Juli
Verwandte Märkte
Hantavirus pandemic in 2026?
91.030,8 €Ja: 3%
POLYMARKET
POLYMARKET
# of views of MrBeast video day 3?
12.927,7 €26-27M: 93%POLYMARKET
POLYMARKET
Ebola pandemic in 2026?
4904,6 €Ja: 3%POLYMARKET
POLYMARKET
Measles cases in 2026?
2929,4 €Above 3000: 94%KALSHI
KALSHI
Pandemic in 2026?
2059,6 €Ja: 5%KALSHI
KALSHI
Cyclosporiasis cases reported in the US in 2026?
1163 €Above 20k: 34%KALSHI
KALSHIIn diesen Themen aktiv
Regeln
If the FDA's decision on Brepocitinib by Priovant Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Brepocitinib is an experimental oral pill developed by Priovant Therapeutics that is designed to calm an overactive immune system in people with certain inflammatory diseases.
- Think of it like a circuit breaker for runaway immune signals: it blocks specific molecular switches inside immune cells that, when left unchecked, drive damaging inflammation throughout the body.
- In the VALOR trial , it is being tested as a treatment for dermatomyositis, a rare disease in which the immune system attacks the body's own muscles and skin.